Gelfand J.M., Armstrong A.W., Bell S., Anesi G.L., Blauvelt A., Calabrese C. et al. National psoriasis foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: version 1. J Am Acad Dermatol. 2020;83(6):1704–1716. https://doi.org/10.1016/j.jaad.2020.09.001..
DOI: 10.1016/j.jaad.2020.09.001
Kara Polat A., Oguz Topal I., Karadag A.S., Aksoy H., Koku Aksu A.E., Ozkur E. et al. The impact of COVID-19 in patients with psoriasis: a multicenter study in Istanbul. Dermatol Ther. 2021;34(1):e14691. https://doi.org/10.1111/dth.14691..
DOI: 10.1111/dth.14691
El-Komy M.H.M., Abdelnaby A., El-Kalioby M. How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study. J Cosmet Dermatol. 2021;20(6):1573–1579. https://doi.org/10.1111/jocd.14104..
DOI: 10.1111/jocd.14104
Diotallevi F., Campanati A., Bianchelli T., Bobyr I., Luchetti M.M., Marconi B. et al. Skin involvement in SARS-CoV-2 infection: case series. J Med Virol. 2020;92(11):2332–2334. https://doi.org/10.1002/jmv.26012..
DOI: 10.1002/jmv.26012
Freeman T.L., Swartz T.H. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020;11:1518. https://doi.org/10.3389/fimmu.2020.01518..
DOI: 10.3389/fimmu.2020.01518
Sbidian E., Madrange M., Viguier M., Salmona M., Duchatelet S., Hovnanian A. et al. Respiratory virus infection triggers acute psoriasis flares across different clinical subtypes and genetic backgrounds. Br J Dermatol. 2019;181(6):1304–1306. https://doi.org/10.1111/bjd.18203..
DOI: 10.1111/bjd.18203
Giannoni M., Consales V., Campanati A., Ganzetti G., Giuliodori K., Postacchini V. et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015;29(9):1781–1785. https://doi.org/10.1111/jdv.13023..
DOI: 10.1111/jdv.13023
Jones S.A., Jenkins B.J. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773–789. https://doi.org/10.1038/s41577-018-0066-7..
DOI: 10.1038/s41577-018-0066-7
Saha A., Sharma A.R., Bhattacharya M., Sharma G., Lee S.S., Chakraborty C. Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19. Arch Med Res. 2020;51(6):595–597. https://doi.org/10.1016/j.arcmed.2020.05.009..
DOI: 10.1016/j.arcmed.2020.05.009
Magro G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X. 2020;2(2):100029. https://doi.org/10.1016/j.cytox.2020.100029..
DOI: 10.1016/j.cytox.2020.100029
Wolf J., Rose-John S., Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11–20. https://doi.org/10.1016/j.cyto.2014.05.024..
DOI: 10.1016/j.cyto.2014.05.024
Соболев В.В., Денисова Е.В., Чебышева С.Н., Геппе Н.А., Корсунская И.М. Экспрессия гена IL-6 как маркер патологического состояния при псориазе и псориатическом артрите. Бюллетень экспериментальной биологии и медицины. 2022;173(1):92–95. https://doi.org/10.47056/0365-9615-2022-173-1-92-95..
DOI: 10.47056/0365-9615-2022-173-1-92-95
Pietrzak A., Chabros P., Grywalska E., Pietrzak D., Kandzierski G., Wawrzycki B.O. et al. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Postepy Dermatol Alergol. 2020;37(1):41–45. https://doi.org/10.5114/ada.2018.78028..
DOI: 10.5114/ada.2018.78028
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5..
DOI: 10.1016/S0140-6736(20)30183-5
Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. https://doi.org/10.1001/jama.2020.1585..
DOI: 10.1001/jama.2020.1585
Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7..
DOI: 10.1016/S0140-6736(20)30211-7
Zhao L., Tang Y., You Z., Wang Q., Liang S., Han X. et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS ONE. 2011;6(4):e18909. https://doi.org/10.1371/journal.pone.0018909..
DOI: 10.1371/journal.pone.0018909
Hao S.R., Zhang S.Y., Lian J.S., Jin X., Ye C.Y., Cai H. et al. Liver Enzyme Elevation in coronavirus disease 2019: a multicenter, retrospective, crosssectional study. Am J Gastroenterol. 2020;115(7):1075–1083. https://doi.org/10.14309/ajg.0000000000000717..
DOI: 10.14309/ajg.0000000000000717
Каткова К.В., Плиева К.Т., Денисова Е.В., Жукова О.В., Волнухин А.В., Корсунская И.М. Влияние коронавирусной инфекции на течение псориаза. Медицинский совет. 2021;(12):332–338. https://doi.org/10.21518/2079-701X-2021-12-332-338..
DOI: 10.21518/2079-701X-2021-12-332-338
Корсунская И.М., Пирузян А.Л., Сакания Л.Р., Жукова О.В., Моляренко Е.Н., Соболев В.В. Роль глицирризиновой кислоты в патогенезе псориатической болезни. Эффективная фармакотерапия. 2016;(1-2):24–31. Режим доступа: https://umedp.ru/articles/rol_glitsirrizinovoy_kisloty_v_patogeneze_psoriaticheskoy_bolezni.html.https://umedp.ru/articles/rol_glitsirrizinovoy_kisloty_v_patogeneze_psoriaticheskoy_bolezni.html
Корсунская И.М., Пирузян А.Л., Сакания Л.Р., Жукова О.В., Моляренко Е.Н., Соболев В.В. Роль глицирризиновой кислоты в патогенезе псориатической болезни. Эффективная фармакотерапия. 2016;(1-2):24–31. Режим доступа: https://umedp.ru/articles/rol_glitsirrizinovoy_kisloty_v_patogeneze_psoriaticheskoy_bolezni.html.https://umedp.ru/articles/rol_glitsirrizinovoy_kisloty_v_patogeneze_psoriaticheskoy_bolezni.html
Barone A., Cristiano M.C., Cilurzo F., Locatelli M., Iannotta D., Di Marzio L. et al. Ammonium glycyrrhizate skin delivery from ultradeformable liposomes: a novel use as an anti-inflammatory agent in topical drug delivery. Colloids Surf B Biointerfaces. 2020;193:111152. https://doi.org/10.1016/j.colsurfb.2020.111152..
DOI: 10.1016/j.colsurfb.2020.111152
Passali D., Ciprandi G., Damiani V., De Marco A.M., Cianfrone F., Passali F.M. Glycyrrhizin for topical use and prophylaxis of COVID-19: an interesting pharmacological perspective. J Biol Regul Homeost Agents. 2021;35(Suppl. 2): 15–19. https://doi.org/10.23812/21-1supp2-4..
DOI: 10.23812/21-1supp2-4